The nerve growth factor (NGF) receptor, trkA, the tumour suppressor p53 and the phosphatase SHP-1 are critical in cell proliferation and differentiation. SHP-1 is a trkA phosphatase that dephosphorylates trkA at tyrosines (Y) 674 and 675. p53 can induce trkA activation and tyrosine phosphorylation in the absence of NGF stimulation. In breast cancer tumours trkA expression is associated with increased patient survival. TrkA protein expression is higher in breast-cancer cell lines than in normal breast epithelia. In cell lines (but not in normal breast epithelia) trkA is functional and can be NGFstimulated to promote cell proliferation. This study investigates the functional relationship between trkA, p53 and SHP-1 in breast-cancer, and reveals that in wildtype (wt) trkA expressing breast-cancer cells both endogenous wtp53, activated by therapeutic agents, and transfected wtp53 repress expression of SHP-1 through the proximal CCAAT sequence of the SHP-1-P1-promoter and the transcription factor NF-Y. In these cells trkA-Y674/Y675 phosphorylation is detected when SHP-1 protein levels decrease in a wtp53-dependent manner. Proliferation and cell-cycle assays, with cells expressing endogenous or transfected wt-trkA and a temperature-sensitive p53 grown at 32 1C (when p53 is in the wt configuration), show suppressed cell proliferation. Suppression is not detected when grown at 37 1C (when p53 is in the mutant configuration). A release from suppression is observed when these cells are transiently transfected with wt-SHP-1 and grown at 32 1C. Suppression is also detected when, as control, wt-trkA-expressing cells are transiently transfected with SHP-1-siRNA, but not when a dominant-negative (DN) mutant trkA is used to abolish wt-trkA activity. Importantly, suppression is not seen with control trkA-negative breast-cancer cells (expressing wtp53, wt-SHP-1 and undetectable trkA), transfected with Y674F/Y675F mutant-trkA. BrdUincorporation experiments reveal lack of incorporation in cells expressing wt-trkA and wtp53, or wt-trkA and SHP-1-siRNA. However, BrdU is incorporated in the presence of Y674F/Y675F mutant trkA or DN mutant trkA. These results indicate that p53 repression of SHP-1 expression leads to trkA-Y674/Y675 phosphorylation and trkA-dependent suppression of breast-cancer cell proliferation. These data provide an explanation as to why high trkA levels are associated with favourable prognosis.
Introduction
The nerve growth factor (NGF) receptor, trkA, and the tumour suppressor p53 are important in survival, differentiation and proliferation of neoplastic and nonneoplastic breast epithelial cells. NGF stimulation of trkA promotes trkA activation and tyrosine phosphorylation (Reichardt, 2006) . Phosphorylation of tyrosines 490 (Y490) and 785 (Y785) initiates signalling that promotes survival, proliferation or differentiation in a tissue-specific manner (Kaplan and Miller, 2000; Reichardt, 2006) . p75, the low-affinity NGF receptor, interacts with trkA to form a high-affinity NGF-binding receptor (Gentry et al., 2004) . Analysis of trkA, p75 and NGF in human breast carcinomas shows trkA and p75 expression associated with increased survival, whereas tumours expressing NGF and low p75 levels have poor prognosis (Sakamoto et al., 2001; Descamps et al., 2001a; ReisFilho et al., 2006) . trkA protein expression is higher in breast-cancer cell lines than in normal breast epithelia. In breast-cancer cell lines (but not in normal breast epithelia) trkA is functional and can be NGF-stimulated to promote proliferation (Descamps et al., 1998 (Descamps et al., , 2001b .
p53 is a family member of related genes (p73 and p63) that share similar functions (Moll and Slade, 2004) . p53 induces tumour suppression by transcriptionally activating or repressing gene expression by binding to transcription factors such as NF-Y (Ho and Benchimol, 2003; Imbriano et al., 2005) . p53 has nuclear localization and exclusion signals, and exhibits nuclear or cytoplasmic localization (Shaulsky et al., 1991; Stommel et al., 1999) . Although p53 mutation incidence in breastcancer is 20-30% (Feki and Irminger-Finger, 2004; Olivier et al., 2004) , breast tumours and cell lines show detectable wild-type (wt)p53 located preferentially in the cytoplasm, suggesting that cytoplasmic sequestration abrogates its tumour-suppressing activity (Moll et al., 1992 (Moll et al., , 1996 .
We have shown that p53 is involved in trkA signal transduction. In PC12 cells exogenous or endogenous p53 can bind trkA. trkA and p53 association occurs only in the presence of the non-receptor tyrosine kinase, c-abl (Montano, 1997; Brown et al., 2000; Browes et al., 2001) . Overexpressed p53 induces trkA activation and tyrosine phosphorylation together with survival and differentiation of PC12 cells expressing trkA when grown in the absence of NGF, suggesting that p53 and trkA association, and p53-dependent trkA activation and tyrosine phosphorylation promote signals leading to PC12 cell differentiation in the absence of NGF (Montano, 1997; Brown et al., 2000) .
The maintenance of tyrosine phosphorylation homoeostasis is regulated by protein tyrosine kinases and phosphatases. The phosphatase SHP-1 is mainly a cytosolic protein, and its expression in haematopoietic cells can negatively regulate signalling from receptors such as CSF-1, by tyrosine dephosphorylation of the target receptor or receptor-associated tyrosine-phosphorylated proteins (Neel et al., 2003) . SHP-1 is also expressed in non-haematopoietic normal and malignant epithelial cells (Yip et al., 2000) , the nervous system (Horvat et al., 2001) and PC12 cells (Vambutas et al., 1995) .
SHP-1 is a trkA phosphatase that binds to trkA through Y490, and dephosphorylates tyrosines 674 (Y674) and 675 (Y675) of the activation loop (Marsh et al., 2003) . Y674/Y675 phosphorylation is critical for the regulation of trkA catalytic activity and transphosphorylation of Y785 and Y490 (Cunningham et al., 1997) . In addition, SHP-1 interacts with the thyroid-TRK-fused oncogene, TRK-T3 (Roccato et al., 2005) . This paper reports that breast-cancer cells expressing endogenous or transfected wt-trkA, endogenous wtp53 activated by chemotherapeutic agents or transfected wtp53 repress SHP-1 expression and promote trkA-Y674/Y675 phosphorylation. Importantly, expression of wt-trkA (but not Y674F/Y675F mutant trkA) and wtp53-repressed SHP-1-expression leads to breast cancer cell-cycle arrest suggesting an important function for wt-trkA in this event.
Results

Repression of expression through SHP-1-P1 by wtp53
The human SHP-1 gene possesses two promoters for tissue-specific transcription. The P1 promoter (SHP-1-P1) is active in non-haematopoietic cells (Banville et al., 1995; Xu et al., 2001) . SHP-1-P1 contains proximal (P) and distal (D) CCAAT consensus sequences recognized by the NF-Y transcription factor (Xu et al., 2001) . CCAAT-containing promoters are repressed by p53 through NF-Y (Imbriano et al., 2005) . Because breast-cancer cell lines express cytosolic SHP-1 (Yip et al., 2000) , trkA tyrosine phosphorylation induced by p53-repressed SHP-1 expression by SHP-1-P1 was investigated.
SHP-1-P1 (nucleotides À469 to þ 1) from MCF7 cells was cloned into pGL2 to obtain a SHP-1-P1 luciferase reporter (pSHP-1-P1-lu). MCF7 cells expressing endogenous wtp53 and wt-trkA, and Saos2 cells (osteosarcoma cell line without trkA and p53 expression), were transiently co-transfected with pSHP-1-P1-lu and wtp53. Results showed 30.3-and 13.9-fold repression of luciferase activity by wtp53, respectively, when compared to transfections of pSHP-1-P1 alone ( Figure 1A1-2) . Control co-transfections with pSHP-1-P1-lu and mutant p53-R273H or p53-R175H, and transfection of MCF7 cells expressing the dominantnegative (DN) mutant p53-DD (Shaulian et al., 1992) with pSHP-1-P1-lu showed low repression ( Figure 1A1-2) . Similar results were obtained with pSHP-1-P1-lu and pCMV co-transfections (data not shown). A comparison between pSHP-1-P1-lu and wtp53 with pSHP-1-P1-lu and mutant p53 co-transfections, and transfections with SHP-1-P1 alone, showed significantly high wtp53-dependent repression (t-test, po0.001). The finding that repression was higher in MCF7 than Saos2 cells was probably due to the additive effect of endogenous and transfected wtp53.
To assess if SHP-1-P1 repression is detected with exogenous p53 and trkA, MCF7 cells were stably cotransfected with a murine temperature-sensitive (ts) p53val135 mutant (Michalovitz et al., 1990) and human wt-trkA (MCF7-trkA-tsp53), and a colony expressing 2-to 3-fold more wt-trkA than endogenous wt-trkA and similar tsp53 as endogenous wtp53 levels was selected ( Figure 1B ). MCF7-trkA-tsp53 cells transiently transfected with pSHP-1-P1-lu grown at 32 1C (wt configuration p53) showed 6-fold repression ( Figure 1A1 ). Because tsp53val135 is a 'leaky' mutant (Montano, 1997) , lack of similar repression levels to wtp53 and pSHP-1-P1 co-transfected MCF7 cells could be due to some mutant p53 expression in cells grown at 32 1C. As control for activation and repression, pG13-lu (with 13 tandem wtp53-binding sites) and CDC2 promoter, cotransfected with wtp53, were used. wtp53 activated or repressed expression (el-Deiry et al., 1992; Yun et al., 1999 ) from pG13-lu or pCDC2-P-lu respectively ( Figure 1A1 -2). Co-transfection of wtp53 with pM15-lu (with 15 tandem mutant p53-binding sites) or pGL2 showed very low activity ( Figure 1A1 -2). Activity was not seen with pGL2, pG13-lu, pM15-lu or pCDC2-P-lu and p53-R273H or p53-R175H co-transfections (data not shown).
Treatment of cells expressing endogenous wtp53 with chemotherapeutic drugs promotes activation and increased p53 levels as a physiological response (Meek, 2004) . To assess if endogenous wtp53 represses SHP-1-P1 activity, MCF7, MDA-MB-231 and T47D cells were transiently transfected with pSHP-1-P1-lu, pG13-lu, pM15-lu or pGL2, or co-transfected with pSHP-1-P1-lu and p53-R175H or pCMV, and incubated with actinomycin D (ActD) or cisplatin (Cis). MCF7 cell treatment with 15 nM ActD for 16 h or 20 mM Cis for 12 h induced endogenous wtp53 activation to promote a 4.2-and 3.8-fold repression respectively ( Figure 1C1 ). Incubation with 15 nM ActD for 24 h induced a 7.5-fold p53 repression of SHP-1 induces trkA-dependent growth arrest X Montano repression (data not shown). Repression was very low in pSHP-1-P1-lu and p53-R175H co-transfections and activation was detected with pG13-lu ( Figure 1C1 ). Repression or activation was not seen with mutant p53 MDA-MB-231-and T47D-expressing cells ( Figure 1C2-3) ; however, pSHP-1-P1-lu activity was not as high as in MCF7 cells. SHP-1 promoter methylation represses SHP-1 expression in MDA-MB-231 cells (Ostman et al., 2006) and lowers its expression in T47D cells (Wu et al., 2003) . Because they express mutant p53 (Concin et al., 2003) , it is possible that lower exogenous SHP-1-P1 activity is due to a p53-independent mechanism such as promoter methylation. Together these results suggest that exogenous and activated endogenous wtp53 repress expression from SHP-1-P1.
P-CCAAT and NF-Y are involved in repression by wtp53 through SHP-1-P1 To identify DNA sequences involved in p53-dependent repression, SHP-1-P1-nested deletion mutants at 5 0 nucleotide position À410, À343, À315, À282, À240 or À96, and SHP-1-P1 with mutated P-CCAAT and adjacent sequences (À72 to À59) or mutated D-CCAAT (À332 to À328) were produced, subcloned into pGL2 and transiently co-transfected with pCMV or wtp53 into MCF7 cells. Although comparison between p53-repressed versus -non-repressed luciferase activity showed some repression with À410, À343, À315, À282, À240 or À96 SHP-1-P1 mutants, a significant low 4.9-fold repression with mutant pSHP-1-P1-P-CCAAT when compared to a 35.1-fold with wt SHP-1-P1 was observed ( Figure 1D ), suggesting that primarily P-CCAAT and adjacent sequences are involved in p53-dependent repression through SHP-1-P1. The NF-Y transcription factor, consisting of NF-YA, NF-YB and NF-YC subunits (Mantovani, 1999) , is involved in p53-dependent repression. To assess if p53 and NF-Y recognize P-CCAAT of SHP-1-P1, chromatin immunoprecipitation (ChIP) assays were undertaken using lysates of ActD-treated MCF7 cells. Only antip53-DO-1 or anti-NF-YB antibodies precipitated SHP-1-promoter DNA as shown after PCR amplification ( Figure 1E ). As expected (Wasner et al., 2003; Spiesbach et al., 2005) , p53 and NF-Y recognized the cyclin B2 promoter but not the BACE promoter ( Figure 1E ). Thus p53 represses SHP-1-P1-driven expression through P-CCAAT, and NF-Y is involved in this activity.
SHP-1 protein expression is repressed by wtp53
To determine if activated wtp53 induces repression of SHP-1 protein expression, endogenous wtp53 and wt-SHP-1 protein levels from ActD-or UV-treated MCF7 cells were assessed. A 2.5-and 4.5-fold increase in p53 and a decrease of 45-50% and 80-85% in SHP-1 levels were observed after ActD or UV treatment respectively (Figure 2a ). MCF7-trkA-tsp53 cells grown at 32 1C showed a 45-50% decrease in SHP-1 expression (Figure 2a) . A decrease was not seen in T47D (expressing wt-SHP-1), MDA-MB-231 (without SHP-1 expression), MDA-MB-157 cells (without p53 and SHP-1 expression) (Yip et al., 2000) or in MCF7-trkA-tsp53 cells grown at 37 1C. A decrease in control CDC2 expression was detected in MCF7 cells, but not in T47D, MDA-MB-231, MDA-MB-157 cells or MCF7-trkAtsp53 cells grown at 37 1C (Figure 2a ). Increased p53 and decreased SHP-1 levels were also seen in ActDor UV-treated ZR75-1 cells (expressing endogenous wt-trkA and wtp53), but not in MCF7-p53-RNAi cells (Berns et al., 2004) with siRNA-ablated p53 expression (Supplementary Figure 1) .
Repression was also detected at the mRNA level. RNA from ActD-treated and non-treated MCF7, ZR75-1 cells and murine p53À/À fibroblasts subjected to reverse transcription (RT)-PCR showed decreased SHP-1 mRNA expression in MCF7 and ZR75-1 but not in p53À/À cells after ActD treatment (Figure 2b ). As control, increased p21 and decreased CDC25 mRNA levels by wtp53 were observed (the sizes of SHP-1, p21 and CDC25 RT-PCR amplified products are smaller from mouse than from human cells). Thus repression of SHP-1 protein and mRNA expression are detected only in the presence of wtp53.
Repression of SHP-1 expression by wtp53 leads to wt trkA-Y674/Y675 phosphorylation Chemotherapeutic drugs activate receptor tyrosine kinases through mechanisms such as oxidative stress or by activating protein kinases (Benhar et al., 2002; El-Abaseri et al., 2006) . To test if ActD promotes trkA tyrosine phosphorylation, in the absence of p53, trkA was immunoprecipitated from NGF-stimulated or ActD-treated non-transfected or wt-trkA stably transfected p53À/À fibroblasts, and analysed by immunoblotting with 4G10 antibodies. ActD did not induce trkA tyrosine phosphorylation. Phosphorylation was only detected in the presence of NGF (Figure 3a1 ). Lysates from p53À/À ActD-treated cells revealed lack of SHP-1 repression (Figure 3a2 ), whereas control NIH3T3 ActD-treated cells showed increased p53 and decreased SHP-1 levels respectively.
To assess if SHP-1 repression leads to trkA tyrosine phosphorylation, ActD was used. Lysates from MCF7 cells treated with NGF, ActD and trkA inhibitor, K252a, were immunoblotted with anti-trkA-phospho-Y674/Y675 antibodies. 35% Y674/Y675 phosphorylation was observed in ActD-treated cells when compared to NGF-stimulated cells. Phosphorylation was not detected in the presence of K252a. Increased p53 and decreased SHP-1 levels were observed in ActD presence ( Figure 3b1 ). MCF7 cells stably expressing 2-to 3-fold more wt-trkA than endogenous wt-trkA (MCF7-trkA) (Supplementary Figure 2) or MCF7-trkA-tsp53 cells grown at 32 1C showed Y674/Y675-phosphorylated when ActD-treated or grown at 32 1C at 26 and 27% respectively ( Figure 3b2 ). Phosphorylation was not seen in K252a-incubated MCF7-trkA cells or MCF7-trkAtsp53 cells grown at 37 1C. Increased p53 and decreased SHP-1 levels were observed in ActD-treated cells or cells grown at 32 1C (Figure 3b2 ). Therefore, exogenous or endogenous wt-trkA is Y674/Y675-phosphorylated when p53 represses SHP-1 expression.
p53 repression of SHP-1 induces trkA-dependent growth arrest X Montano
As positive control, MCF7-trkA and MCF7-trkAtsp53 cells were transiently transfected with a DN mutant SHP-1 (D-SHP-1; Timms et al., 1998) or SHP-1-siRNA. In the presence of D-SHP-1, 24 and 22% trkA was Y674/Y675-phosphorylated in the absence of NGF and presence of ActD, respectively, and 28 and 26% was observed when grown at 32 or 37 1C. In the presence of SHP-1-siRNA, 18 and 20% phosphorylation was detected in the absence of NGF or presence of ActD, respectively, and 20 and 16% when grown at 32 or 37 1C (Figure 3b3-4) . Phosphorylation was not seen in non-transfected cells, in the presence of K252a, control-siRNA or wt-SHP-1 (Supplementary Figure 3) . SHP-1-siRNA induced a decrease in SHP-1 levels ( Figure 3b3 Repression of SHP-1 expression by wtp53 suppresses breast-cancer cell proliferation in the presence of wt-trkA Erb-2 and the epidermal growth factor receptor (EGFR) are involved in breast-cancer (Mosesson and Yarden, 2004) . SHP-1 dephosphorylates EGFR at tyrosine 1173 (Keilhack et al., 1998) , but there is no evidence that it dephosphorylates Erb-2 (Vadlamudi et al., 2002) . To assess if SHP-1 repression influences endogenous EGFR tyrosine phosphorylation, MCF7 and ZR75-1 cells were transfected with SHP-1-siRNA or control-siRNA. EGFR immunoprecipitates from EGF-stimulated and non-stimulated cells, immunoblotted with 4G10, showed EGF-stimulated EGFR tyrosine phosphorylation in SHP-1-siRNA-transfected cells, to levels similar to nontransfected cells (Figures 4a and b) , suggesting that repression of SHP-1 expression does not affect full EGFR tyrosine phosphorylation.
To determine if p53-dependent SHP-1 repression is involved in breast-cancer cell proliferation, MTT assays were carried out. As EGFR can be tyrosine-phosphorylated when SHP-1 is repressed, assays were undertaken in the presence of EGFR-siRNA to assess the specific Figure 1 (A) Repression of SHP-1-P1-driven luciferase expression by wtp53. MCF7 or Saos2 cells were transiently transfected with 1.5 mg pSHP-1-P1-lu, pGL2, pG13-lu, pM15-lu or pCDC2-P-lu or co-transfected with 1.5 mg pSHP-1-P1-lu, pGL2, pG13-lu, pM15-lu or pCDC2-P-lu and 2 mg of pCMV-wtp53-, p53-R175H-or p53-R273H-containing vectors. MCF7 cells expressing p53-DD or MCF7-trkA-tsp53 cells were transiently transfected with 1.5 mg pSHP-1-P1-lu. For all transfections 0.3 mg of a Renilla containing vector was used as internal control. Cells were grown for 48 h at 32 1C (32) or 37 1C (37) and lysates were assayed for luciferase expression. Normalized luciferase activity in cell extracts was determined in triplicate and expressed relative to the activity of cells transiently transfected with pCMV empty vector. Error bars indicate standard deviations. (1) MCF7 cells, MCF7 cells expressing p53-DD (p53-DD) and MCF7-trkA-tsp53 cells. (2) Saos2 cells (experiments assessed in triplicate). (B) Expression of murine tsp53 and wt-trkA in MCF7. MCF7 cells were stably co-transfected with wt-trkA and a colony expressing 2-to 3-fold more wt-trkA, when compared to endogenous wt-trkA, was selected and transfected with a murine tsp53 mutant, then a colony that expressed the same tsp53 levels as endogenous wtp53 in MCF7 cells (MCF7-trkA-tsp53) was obtained. Similar amounts of (1) MCF7-trkA-tsp53 and (2) MCF7 cell lysates were immunoprecipitated with anti-p53 PAb-DO1 (which recognizes only human p53) or PAb248 (which recognizes only murine p53) antibodies and subjected to 7.5% SDS-polyacrylamide gel electrophoresis (PAGE). The presence of p53 was determined by immunoblotting with sheep anti-p53 antibodies that recognize human and murine p53. Immunoprecipitation with PAb-DO1 and PAb248 demonstrates the presence of human and mouse p53 and p53b isoform respectively (Bourdon et al., 2005) . As published human and murine p53, when co-expressed, heteroligomerize and co-immunoprecipitate (Milner and Medcalf, 1991) , thus, human and murine p53 can be seen in PAb248 and PAb-DO1 immunoprecipitates. (3) Similar amounts of MCF7-trkA-tsp53 and MCF7 cell lysates were immunoprecipitated with anti-trkB3 antibodies and subjected to 7.5% SDS-PAGE. The presence of trkA was determined by immunoblotting with anti-trk203 antibodies. (C) Repression of SHP-1-P1-driven luciferase expression by actinomycin D-or cisplatin-activated endogenous wtp53. MCF7, T47D or MDA-MB-231 cells were transiently transfected with 0.5 mg pSHP-1-P1-lu, pGL2, pG13-lu, pM15-lu or pCDC2-P-lu or co-transfected with 0.5 mg pSHP-1-P1-lu and 1 mg of p53-R175H containing vectors. In all cases 0.3 mg of Renilla containing vector was used as internal control. Cells were left to grow for 24 h following transfection and then were incubated with 20 mM cisplatin for 12 h or 15 nM actinomycin D for 16 h. Cell lysates were assayed as described in (A). It is critical to indicate that to show assay sensitivity, a lower plasmid concentration, than the one used for analysis in (A), was chosen for these experiments. (1) MCF7 cells, (2) T47D cells, (3) MDA-MB-231 cells (experiments assessed in triplicate). (D) P-CCAAT from the SHP-1-P1 promoter is involved in repression by wtp53. Schematic diagram of the wt SHP-1-P1 promoter showing the sites of NF-kB, distal CCAAT (D-CCAAT), SP1 and proximal CCAAT (P-CCAAT) sequences, and nested deletion mutants at 5 0 nucleotide positions À410, À343, À315, À282, À240 and À96. pSHP-1-P1-D-CCAAT and pSHP-1-P1-CCAAT mutants show lack of D-CCAAT and P-CCAAT sequences respectively. MCF7 cells were transiently co-transfected with 1.5 mg of pSHP-1-P1-lu, 5 0 nested deletion SHP-1-P1 mutants, pSHP-1-P1-D-CCAAT or pSHP-1-P1-CCAAT mutant containing vectors and 2 mg of pCMV-wtp53 or co-transfected with 1.5 mg pSHP-1-P1-lu or pSHP-1-P1-lu mutants together with 2 mg pCMV empty vector. Renilla containing vector (0.3 mg) was used as internal control. Cells were grown for 48 h and lysates were assayed for luciferase expression. Normalized luciferase activity in cell extracts was determined in triplicate. The fold repression effects were calculated by dividing relative luciferase in the presence of pCMV by the one obtained in the presence of pCMV-wtp53 (experiments assessed in triplicate). (E) Detection of NF-Y and wtp53 binding to wt-P-CCAAT by chromatin immunoprecipitation (ChIP) assays. MCF7 cells were incubated with 15 nM actinomycin D for 24 h and lysates were subjected to ChIP with 2 mg of anti-NF-YB antibodies, anti-p53 PAb-DO1 or control IgG. Cyclin B2 and BACE promoters served as positive and negative controls respectively. PCR was carried out with the indicated oligonucleotide primers. In the input lane only one-third of the sample volume was loaded onto the gel (these are representative of six experiments).
p53 repression of SHP-1 induces trkA-dependent growth arrest X Montano function of trkA. Proliferation was decreased in MCF7 and ZR75-1 cells transiently transfected with tsp53 when grown at 32 1C but not at 37 1C (Figure 5a1-2) . A decrease was detected in positive control SHP-1-siRNA but not in control-siRNA transfections (Figure 5a1-2) . Moreover, MCF7 and ZR75-1 cells co-transfected with p53 repression of SHP-1 induces trkA-dependent growth arrest X Montano tsp53 and wt-SHP-1 grown at 32 1C showed increased proliferation similar to cells grown at 37 1C and nontransfected cells (Figure 5a1-2) . A temperature change did not induce significant proliferative changes of nontransfected cells. Similar results were obtained with MCF7-trkA-tsp53 cells, and SHP-1-siRNA decreased proliferation when grown at both temperatures ( Figure  5a3 ). wt-SHP-1 transfection of MCF7-trkA cells did not significantly increase proliferation (Figure 5a4 ). However, SHP-1-siRNA induced a decrease at 32 or 37 1C (Figure 5a4 ). Although the control-siRNA was effective (Figure 5a ), as expected (Downward, 2004) , low background activity was sometimes detected. When similar analysis was undertaken using a DN ATP K538 kinasedead mutant trkA (trkA-KD) (Esposito et al., 2001) , suppressed proliferation was abolished ( Supplementary  Figure 5a1-4) .
To define the function of trkA, MDA-MB-361 cells not expressing or expressing trkA-Y674F/Y675F and tsp53, trkA-Y674F/Y675F, tsp53 and wt-SHP-1 or tsp53 alone were analysed. Minor but not significant proliferative changes were seen (Figure 5b1 ). However, a decrease was observed in wt-trkA and tsp53 cell co-transfections grown at 32 1C (Figure 5b2 ). Expres- Figure 2 (a) Repression of SHP-1 protein expression by endogenous wtp53 activated by actinomycin D (ActD), UV and overexpressed p53. MCF7, T47D, MDA-MB-231, MDA-MB-157 cells were not incubated (À), incubated with 15 nM ActD for 24 h or exposed to 15 kJ UV (UV). Similar amounts of cell lysates were subjected to 8.5% SDS-polyacrylamide gel electrophoresis, analysed by immunoblotting, and when necessary, blot stripping and re-probing for the presence of SHP-1 with rabbit anti-SHP-1 antibodies, p53 with PAb-DO1 (which only recognizes human p53), CDC2 with rabbit anti-CDC2 antibodies or actin with rabbit anti-actin antibodies. Extracts of MCF7-trkA-tsp53 cells grown at 32 1C (32) or 37 1C (37) were subjected to the same analysis (this is a representative of three experiments). Following incubation with anti-actin antibodies, actin was detected by shorter exposure (left-hand panel). (b) Repression of SHP-1 mRNA expression assessed by reverse transcription (RT)-PCR. Total RNA from MCF7, ZR75-1 cells and murine p53À/À fibroblasts incubated ( þ ) or not incubated (À) with 15 nM ActD for 24 h was prepared and subjected to RT-PCR analysis using the indicated oligonucleotide primers. Levels were standardized to the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH; these are representative of six experiments). (1) Similar amounts of lysates from fibroblasts p53À/À mice, and p53À/À cells stably transfected with wt-trkA (p53À/À trkA) incubated in the presence or absence (À) of 15 nM ActD for 24 h, or stimulated with 100 ng/ml of NGF for 5 min, were immunoprecipitated with anti-trkB3 antibodies, subjected to 7.5% SDS-polyacrylamide gel electrophoresis (PAGE) and analysed by immunoblotting followed by blot stripping and re-probing, for the presence of tyrosine-phosphorylated trkA with 4G10 antibodies and the presence of trkA with rabbit anti-trk203 antibodies (this is a representative of three experiments). (2) NIH 3T3 and p53À/À cells were incubated in the presence ( þ ) or absence (À) of 15nM ActD for 24 h. Similar amounts of cell lysates were immunoprecipitated with anti-SHP-1 or anti-p53 PAb248 (which recognizes only murine p53) antibodies, subjected to 7.5% SDS-PAGE and analysed by immunoblotting. The presence of SHP-1 and p53 was determined with rabbit anti-SHP-1 or Sheep anti-p53 antibodies respectively (this is a representative of three experiments). (b) ActD-activated endogenous or overexpressed wtp53 leads to repression of SHP-1 protein expression and phosphorylation of trkA Y674/Y675. MCF7 cells or MCF7 cells transfected with wt-trkA (MCF7-trkA) were treated as follows: (a) non-stimulated (ÀNGF) or (b) stimulated ( þ NGF) with 100 ng/ml NGF for 5 min, (c) incubated with 15 nM ActD (ActD) for 24 h, (d) incubated with 15 nM ActD and 100 nM K252a for 24 h or (e) incubated with 100 nM K252a for 24 h and stimulated with 100 ng/ml NGF for 5 min. MCF7-trkA-tsp53 cells were grown at 32 1C (32) or 37 1C (37) for 48 h. MCF7-trkA cells transiently transfected with pCMV-D-SHP-1, SHP-1-siRNA or control-siRNA were treated and grown as described. MCF7-trkA-tsp53 were transiently transfected with pCMV-D-SHP-1, SHP-1-siRNA or control-siRNA and grown at 32 or 37 1C for 48 h. Similar amounts of cell lysates were subjected to 7.5% SDS-PAGE and analysed by immunoblotting, and when necessary, blot stripping and re-probing for the presence of phosphorylated trkA with anti-pY674/pY675 antibodies, trkA with anti-trk203, SHP-1 with rabbit anti-SHP-1 antibodies, p53 with PAb-DO1 or actin with anti-actin antibodies. Figures 6a and b) , suggesting that p53 repression of SHP-1 expression requires trkA-Y674/Y675 to induce suppression of proliferation. PDGFR was also selected p53 repression of SHP-1 induces trkA-dependent growth arrest X Montano as it may be involved in breast-cancer (Carvalho et al., 2005) and SHP-1 is a possible PDGFR phosphatase (Yu et al., 1998) .
Because MTT assays quantitate viable cell number, it is possible that effects on either survival or proliferation were measured. Lack of Trypan blue assimilation, DNA fragmentation and caspase-3/7 activation (data not shown) demonstrated that apoptosis was not the cause of reduced proliferation. Therefore cell-cycle status was investigated by propidium iodide staining by flow cytometry. An increase of B80% in cells at G 0 /G 1 in MCF7 transfected with tsp53 or MCF7-trkA-tsp53 cells grown at 32 1C was seen, but was not observed when grown at 37 1C or in non-transfected cells. Transfection of wt-SHP-1 induced a decrease in the G 0 /G 1 population in cells expressing trkA and tsp53 grown at 32 1C (Figure 5c1) . Importantly, wt-trkA-and tsp53-cotransfected MDA-MB-361 cells, subjected to the same analysis, showed a significant increase in the G 0 /G 1 population. Although some increase in G 0 /G 1 population was observed in cells expressing tsp53 alone or Y674F/Y675F-trkA and tsp53 (consistent with a function for p53 in inducing cell-cycle arrest (Stiewe, 2007 ) ), this was not as high as when wt-trkA was present, indicating that trkA is involved in reducing breast cancer cell-cycle progression (Figure 5c2 ).
In addition, MCF7 or ZR75-1 cells non-transfected or transiently transfected with tsp53, wt-SHP-1, SHP-1-siRNA or control-siRNA were grown at 32 or 37 1C, incubated with BrdU and stained with anti-BrdU antibodies. BrdU incorporation (28 and 40%) was detected in tsp53-transfected MCF7 or ZR75-1 cells, respectively, when grown at 32 1C, whereas B95% incorporation was seen when grown at 37 1C (Figures 6a  and c) . MCF7 or ZR75-1 cells co-transfected with tsp53 and wt-SHP-1 showed increased incorporation of 85 and 80%, respectively, when grown at 32 1C (Figures 6a and c) . No significant difference in incorporation was observed in non-transfected cells. MCF7 or ZR75-1 cells transfected with SHP-1-siRNA showed decreased incorporation to 22 and 27%, and 23 and 30% at 32 or 37 1C respectively (Figures 6a and c) . Similar results were seen with MCF7-trkA-tsp53 cells grown at 32 1C or SHP-1-siRNA presence (Figure 6e) . Incorporation was observed in control-siRNAtransfected MCF7-trkA cells or MCF7-trkA-tsp53 cells grown at 37 1C. As expected, wt-SHP-1 or trkA-KD promoted increased BrdU incorporation (Figures 6b, d and f) .
Similar results were obtained with EGFR-siRNA or RISC-Free control-siRNA (data not shown), and EGFR, Erb-2 or PDGFR pharmacological inhibitors ( Supplementary Figure 7a-f) . When MDA-MB-361 cells were transiently co-transfected with trkA-Y674F/Y675F and tsp53 or transfected with tsp53 alone, 75 and 85% BrdU incorporation, respectively, was observed in trkA-Y674F/Y675F and tsp53 co-transfected cells grown at 32 or 37 1C, and 71 and 88% incorporation, respectively, was detected in tsp53 transfected cells grown at either temperature (Figure 6g ). This is consistent with a function of wtp53 in promoting cell-cycle arrest. However, wt-trkA and tsp53 co-transfection showed a decrease to 22% in cells grown at 32 1C, suggesting a function for trkA. A comparison between results from co-transfections of wt-trkA and tsp53 with transfections of tsp53 alone and co-transfections of Y674F/Y675F-trkA and tsp53 showed significant high wt-trkAdependent cell-cycle arrest (t-test, Po0.001). wt-trkA, wt-SHP-1 and tsp53 co-transfection revealed 85% incorporation in cells grown at 32 1C, and co-transfections with wt-trkA and SHP-1-siRNA showed decreased incorporation. No significant decrease was seen with control-siRNA or transfections with SHP-1-siRNA or control-siRNA alone (Figure 6g ). Increased incorporation was observed in the presence of trkA-KD (Figure 6h ), indicating that trkA is involved in repression of BrdU incorporation.
These results demonstrate that endogenous or exogenous phosphorylated wt trkA-Y674/Y675 is involved in suppression of breast cancer cell proliferation promoted by p53 repression of SHP-1 expression.
Discussion
This investigation shows that in breast-cancer cells p53 repression of SHP-1 expression leads to trkA-Y674/ Y675 phosphorylation and suppression of proliferation in the presence of wt-trkA (Figure 7 ). This can be to À96 SHP-1-P1 mutants, suggesting that these sequences can influence on p53-dependent repression. This could be due to changes in promoter conformation induced by DNA deletion, or loss of NF-kB, D-CCAAT or Sp1 consensus sequences (Xu et al., 2001) . However, mutation of P-CCAAT and adjacent sequences induce low activity, suggesting that they are primarily involved in p53-dependent repression. Importantly, ChIP assays indicate that p53 and NF-Y are involved in wt but not mutant P-CCAAT recognition.
Results also suggest that SHP-1 protein expression is repressed by endogenous wtp53 (but not mutant p53) when activated with ActD or UV, as increased p53 concomitant with decreased SHP-1 expression is observed. This is strengthened by results revealing p53 repression of SHP-1 at the mRNA level. Chemo- Figure 5 (a) wtp53 repression of SHP-1 leads to suppression of breast-cancer cell proliferation in the presence of endogenous or transfected wt-trkA. Cells were non-transfected (0) or transiently co-transfected with epidermal growth factor receptor (EGFR) siRNA or RISC-Free control-siRNA and pCMV-wt-SHP-1 (wt-SHP-1), pLTR-tsp53 (tsp53), SHP-1-siRNA or control-siRNA and plated in 96-well plates. Then cells were washed with serum-free media and incubated at 32 1C (32) or 37 1C (37) in the presence or absence of 100 ng/ml NGF and left to grow for 48 h. MTT assays for proliferation were carried out. Changes in proliferation were calculated by subtracting 48 h cell proliferation by proliferation after initial plating. It is important to indicate that results are presented as proliferation ratios. These were obtained by dividing absorbance values of cells grown in the presence of NGF by values obtained in the absence of NGF. (1) MCF7, (2) ZR75-1, (3) MCF7-trkA-tsp53 and (4) MCF7-trkA (experiments assessed in triplicate). (b) wtp53 repression of SHP-1 expression leads to suppressed breast-cancer cell proliferation of MDA-MB-361 cells in the presence of wt-trkA but not mutant trkA-Y674F/Y675F. Cells non-transfected (0) or transiently co-transfected with EGFR-siRNA or RISC-Free controlsiRNA and pCMV-wt-SHP-1 (wt-SHP-1), pLTR-tsp53 (tsp53), pMEX-trkA (trkA) or pLCNX-Y674F/Y675F-trkA (trkA-Y674F/ Y675F) were plated in 96-well plates. Proliferation was analysed as described in Figure 7a. (1) MDA-MB-361 cells transiently transfected with tsp53, co-transfected with mutant trkA-Y674F/Y675F and tsp53, mutant trkA-Y674F/Y675F, or tsp53 and wt-SHP-1 or tsp53 and wt-SHP-1, (2) MDA-MB-361 cells transiently transfected with wt-trkA, co-transfected with wt-trkA and tsp53 or wt-trkA, tsp53 and wt-SHP-1 (experiments assessed in triplicate). (c) Cell-cycle distribution. (1) MCF7 expressing endogenous or transfected wt-trkA. MCF7, MCF7-trkA or MCF7-trkA-tsp53 cells were non-transfected (À) or transiently transfected with pCMVwt-SHP-1 (wt-SHP-1) and/or pLTR-tsp53 (tsp53) and incubated for 48 h at 32 1C (32) or 37 1C (37), and DNA content was analysed by fluorescence-activated cell sorting (FACS, data shown are representative of three independent experiments). (2) MDA-MB-361 cells expressing transfected wt-trkA or mutant trkA. MDA-MB-361 cells were non-transfected (À) or transiently transfected with different combinations of pCMV-wt-SHP-1 (wt-SHP-1), pLTR-tsp53 (tsp53) pMEX-trkA (trkA) or pLCNX-Y674F/Y675F-trkA (trkA-Y674F/Y675F) and incubated for 48 h at 32 1C (32) or 37 1C (37), and DNA content was analysed by FACS (data shown are representative of three independent experiments).
p53 repression of SHP-1 induces trkA-dependent growth arrest X Montano therapeutic drugs can activate receptor tyrosine kinases (Benhar et al., 2002; El-Abaseri et al., 2006) . Agents such as AraC induce trkA transcription or activation (Jagjit and Anthony, 1998; Xie et al.,
2000)
. Because ActD does not induce trkA tyrosine phosphorylation in the absence of wtp53, ActD was used to assess if p53-dependent SHP-1 repression leads to trkA-Y674/Y675 phosphorylation. Analysis of Figure 6 Repression of SHP-1 expression by wtp53 leads to cell-cycle arrest of breast-cancer cells in the presence of wt-trkA. Cells were plated in 3 cm plates containing collagen-coated coverslips. Then cells were non-transfected or transiently transfected with pCMVwt-SHP-1 (wt-SHP-1), pLTR-tsp53 (tsp53), pMEX-trkA (trkA), pLCNX-trkAY674F/Y675F (trkA-Y674/Y675), SHP-1-siRNA or control-siRNA and incubated for 48 h at 32 1C (32) or 37 1C (37). Otherwise cells were transiently co-transfected with pLCNX-KDtrkA (trkA-KD) and as previously stated. Cells were incubated with BrdU for 4 h and stained with anti-BrdU antibodies followed by Alexa-568-conjugated secondary antibodies. To determine if this type of SHP-1 repression is involved in breast-cancer cell proliferation, MTT assays, propidium iodide staining and BrdU incorporation were carried out. These demonstrated that proliferation was suppressed in cells expressing wt-trkA and wtp53. This was not observed in the presence of wt-trkA and mutant p53, trkA-Y674F/Y675F and tsp53, tsp53 alone or in the presence of trkA-KD indicating that wt-trkA is involved in suppression of proliferation. Although a percentage of MDA-MB-361 cells expressing mutant trkA-Y674F/ Y675F and tsp53 or tsp53 alone undergo cell-cycle arrest, this is low compared to wt-trkA and tsp53 co-transfections, emphasizing the key function of wt-trkA.
Because we have demonstrated that trkA and p53 associate and as trkA binds to SHP-1 (Marsh et al., 2003) , immunoprecipitation experiments were performed to determine whether p53 and SHP-1 bind and if a trkA/p53/SHP-1 trimer can be detected. p53 and SHP-1 association was not detected in immunoprecipitations with anti-p53-PAb248, -p53-PAb421 or anti-SHP-1 antibodies (Supplementary Figure 8a) . In the presence of trkA, it was possible to observe trkA and p53 association but not a trkA/p53/SHP-1 trimer complex (Supplementary Figure 8b) , suggesting that p53 does not modulate SHP-1 through binding, and that p53 and SHP-1 possibly compete for the same trkAbinding site. Although it is possible that physical interaction between trkA and p53 might contribute to the function of trkA in reduction of breast cancer cell proliferation, this study shows that SHP-1 downregulation by p53 in the presence of wt-trkA is one mechanism by which breast-cancer cell proliferation is reduced. Moreover, given that wtp53 expression is seen preferentially in the cytoplasm of breastcancer cells undergoing proliferation (Moll et al., 1996) , these experiments suggest that upon activation, p53 translocates to the nucleus to transcriptionally repress SHP-1 expression resulting in suppressed proliferation.
Because p53-induced repression of SHP-1 expression occurs in the presence of pharmacological or DNAdamaging agents, this finding could be used for therapeutic purposes during the clinical management of wt-trkA, wtp53 and wt-SHP-1 expressing breast tumours. Dephosphorylation of Y674/Y675 (which are catalytic tyrosines) inhibits trkA kinase activity and trkA-dependent signal transduction. NGF-dependent trkA activation and phosphorylation of these tyrosines leads to signal transduction through binding of Grb-2, SHB-2 and APS adaptors. Grb-2-binding induces MAPkinase activation (MacDonald et al., 2000) . SHB-2 and APS binding increases the magnitude of trkA tyrosine phosphorylation and activation, and promote branching of axonal processes of sympathetic neurons (Qian et al., 1998; Qian and Ginty, 2001) . Therefore, in breast-cancer cells this type of repression induces trkA-Y674/Y675 phosphorylation, and possibly activation of these substrates and novel signalling cascades promoting cell-cycle arrest, and this novel mechanism is involved in suppression of proliferation and differential tissuespecific responsiveness of trkA.
Previous studies suggested that Erb-2 interacts with trkA during breast-cancer cell proliferation promoted by NGF-stimulated trkA (Tagliabue et al., 2000) . Because suppressed proliferation was detected with an Erb-2 pharmacological inhibitor, the present research suggests that Erb-2 is not involved in trkA-dependent suppression of proliferation. Although transfection of SHP-1 may have tumour suppressor behaviour in cancer cells lacking SHP-1 expression (for example, those of haematopoietic origin; Ostman et al., 2006) , its involvement in SHP-1 expressing cancer cells is not well understood. This investigation indicates that in breastcancer cells downregulation of SHP-1 expression has tumour-suppressing activity. SHP-1 is a negative regulator of several tyrosine kinases and signalling proteins (Neel et al., 2003) . Thus, the possibility that its repression might affect their function and contribute to breast-cancer cell-cycle arrest cannot be excluded and is under investigation.
Overall these results suggest that repression of SHP-1 expression by p53, in the absence of NGF stimulation, promotes trkA-Y674/Y675 phosphorylation and trkAdependent suppression of breast-cancer cell proliferation. This data provide a possible explanation for why high trkA levels are associated with favourable patient prognosis.
Materials and methods
siRNA and plasmids SHP-1-siRNA, SMARTpool-human-EGFR siRNA4 and RISC-Free siRNA were obtained from Dharmacon Thermo Scientific (Leicester, UK). D-SHP-1 and wt-SHP-1 were subcloned into pCDNA3.1. wt SHP-1-P1 was cloned from p53 repression of SHP-1 induces trkA-dependent growth arrest X Montano MCF7 genomic DNA and mutants produced as described (Supplementary methods). Constructs were sequenced for verification.
Cell culture and transfections
Cell lines were cultured and treated with inhibitors or chemotherapeutic drugs as described (Supplementary methods). MCF7 cells were transfected with pMEX-trkA and murine pLTR-tsp53val-135 as described (Montano, 1997) .
For transient DNA transfections 1 Â 10 7 cells were mixed with 30 mg expression plasmid and electroporated. Cells were grown at 32 or 37 1C for 48 h and exposed to UV, incubated with ActD or NGF.
For transient siRNA transfections 5 Â 10 5 or 1.5 Â 10 4 cells were transfected with 6 or 0.2 mg of siRNA using Oligofectamine and Opti-MEM (Invitrogen, Paisley, UK), and incubated at 32 or 37 1C. After 24 h a second transfection was performed, followed by incubation at 32 or 37 1C with or without ActD or NGF.
Luciferase reporter assays A total of 2 Â 10 4 cells per well were plated in six-well plates. After washing with serum-free medium, cells were transiently transfected or co-transfected with Renilla and plasmids using Lipofectin (Invitrogen). Luciferase activity was analysed in cell lysates using the Dual-Luciferase Assay system (Promega, Southampton, UK).
RT-PCR
RNA was extracted using the Perfect RNA Eukaryotic kit (Eppendorf, Cambridge, UK) and DNase digested with Turbo-DNAse (Ambion, Applied Biosystems, Warrington, UK). First-strand reaction was undertaken with Superscript-II reverse transcriptase (Invitrogen) followed by PCR amplification using primers described (Supplementary methods).
ChIP assays
Confluent cells (80%) were incubated for 10 min with formaldehyde (1% final concentration) (Wasner et al., 2003) . Cross-linking was stopped by incubating for 5 min with glycine buffer (0.125 M final concentration). Plates were rinsed with phosphate-buffered saline (PBS) containing EDTA-free protease inhibitors (Roche, Welwyn Garden City, Hertfordshire, UK) and scraped into PBS. Cell pellets of 5 Â 10 7 cells were incubated for 20 min with cold swelling buffer, vortexed and centrifuged to collect nuclei. Nuclei were incubated in lysis buffer for 10 min on ice and sonicated five times for 10 s. Samples were centrifuged and aliquoted as 1 Â 10 7 cells. Aliquots were pre-cleared with salmon sperm DNA-blocked protein G. Pre-cleared aliquots were centrifuged and supernatant was incubated with antibodies overnight at 4 1C, incubated with blocked protein G for 30 min and centrifuged. Beads were washed with dialysis buffer, centrifuged and washed with wash buffer. Immunocomplexes were eluted by incubating with elution buffer at room temperature for 45 min followed by shaking for 15 min. Eluates were collected by centrifugation. Elution was repeated twice. NaCl (0.3 M final concentration) was added and incubated at 67 1C for 5h. DNA was purified with Genelute PCR Clean-Up kit (Sigma) and re-suspended in TE for PCR amplification. Primer sequence and buffer composition are described (Supplementary methods).
MTT assay A total of 2 Â 10 3 cells per well were plated in 96-well plates with 200 ml media per well as control (Fraser et al., 2003) . Cells were washed with serum-free media, and incubated with serum-free media with or without 100 ng/ml of NGF and dimethyl sulfoxide (DMSO) or 1 mM AG1478, AG825 or AG1295 for 48 h at 32 or 37 1C. Media were removed and 190 ml per well of media with or without the above treatments were added followed by 10 ml per well of a 5 mg/ml MTT (3,(4,5 dimethylthiazol-2-yl) 2,5 diphenyltrtrazolium bromide) solution. Plates were incubated at 32 or 37 1C for 4 h. Media were removed and 190 ml of DMSO and 10 ml of glycine buffer (Supplementary methods) were added and incubated for 10 min at room temperature. Absorbance was read at 550 nm using a Tecan's Sunrise Microplate Reader (Tecan Group Ltd, Ma¨nnedorf, Switzerland).
Cell-cycle analysis Non-transfected or transfected cells were plated at 40-50% confluency and cultured for 4 days at 32 or 37 1C. A total of 5 Â 10 5 cells were harvested, re-suspended in 100 ml of PBS containing 2% fetal calf serum and incubated with 150 ml of PBS containing 1% Triton X-100, 50 ml of 5 mg/ml RNAse and 50 ml of propidium iodide for 15 min at room temperature, and analysed using a BD FACSCalibur (BD Biosciences, Oxford, UK).
BrdU incorporation
Cells were plated in dishes containing collagen-coated coverslips, cultured at 32 or 37 1C for 2 days, or transfected with plasmids or siRNA and cultured for 2 days at 32 or 37 1C with or without 1 mM AG1478, AG825 or AG1295. Cells were incubated for 4 h at 32 or 37 1C with 25 mM BrdU (5 bromo-2-deoxyuridine), washed with PBS and fixed with ice-cold methanol for 5 min, washed with PBS, incubated with chilled 3 M HCl for 10 min at room temperature and neutralized with 0.1 M Tris (Ph 8) for 5-10 min. After washing, cells were incubated with anti-BrdU antibodies (Serotec, AdBSerotec, Kidlington, UK) overnight at 4 1C, then by goat anti-rat Alexa-568-conjugated antibodies for 30 min at room temperature. Coverslips were mounted in 4 0 ,6-diamidino-2-phenyl indole (DAPI) containing mounting media (ProLong Gold antifade with DAPI; Invitrogen), and BrdU incorporation was counted by fluorescence microscopy (Zeiss Axiovert 200, Carl Zeiss, Hertfordshire, UK).
SDS-PAGE, immunoprecipitation and western blotting
Immunoprecipitation, SDS-polyacrylamide gel electrophoresis (PAGE) and western blotting were carried out as described ( (Montano, 1997; Supplementary methods) . EGFR immunoprecipitation was undertaken as described (Buday and Downward, 1993) .
